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M alignancy-associated vasculitis represents only0.4% to 4.2% of all vasculitis cases1–3 and con-
sists mostly of cancer-associated cutaneous leukocyto-
clastic vasculitis.2,4–6 Malignancy-associated systemic
vasculitic syndromes are very rare andmostly associated
with hematological malignancies. Here we report on the
case of a 64-year-old woman in whom perinuclear
autoantibody-associated neutrophilic cytoplasmic anti-
gen (ANCA)-associated vasculitis (AAV) was diagnosed
with a concurrent adenocarcinoma of the gastroesopha-
geal junction. Resection of the tumor resulted in a partial
improvement of her symptoms. Subsequent treatment
with rituximab resulted in a complete and durable
remission of the AAV-associated signs and symptoms.
After more than 1 year of follow-up there were no signs
of recurrence of her malignancy or AAV relapse. This is
the ﬁrst report on the beneﬁcial effect of rituximab on
malignancy-associated vasculitis.
CASE PRESENTATION
A 64-year-old woman was admitted to the hospital with
a 2-month history of anorexia, intermittent fever, fa-
tigue, nightly cough, staggered myalgia, and pares-
thesia in her ﬁngers. She had a medical history of
arterial hypertension, hypercholesterolemia, hyper-
thyroidism, and left-sided Bell’s palsy with complete
recuperation. The ﬁndings of physical examination at
time of presentation were unremarkable except for
those of the neurological examination, which showed
symmetric superﬁcial and deep sensory disturbances
distal in the upper and lower limbs, with overpowered
extension and spreading of the ﬁngers, hip ﬂexion,
knee ﬂexion, and foot extension (Medical ResearchInternational Reports (2016) 1, 131–134Council scale for muscle power grade 3). Reﬂexes were
all present and rather hyperactive, but without clonus.
Electromyography demonstrated an axonal sensori-
motor peripheral neuropathy. Laboratory ﬁndings
showed signs of inﬂammation (minimal leukocytosis;
elevated C-reactive protein level; a normochromic
normocytic anemia with iron deﬁciency; and an acute
kidney injury stage 3 [failure] according to the risk,
injury, loss, and end-stage classiﬁcation) (Table 1).
Urinalysis showed microscopic, dysmorphic hematuria
and limited proteinuria. Renal ultrasonography showed
no abnormalities. Perinuclear ANCAs (1/1280) were
positive against myeloperoxidase with a titer higher
than 134 U/ml (<3.5 ¼ negative, >5 ¼ positive). The
results of testing for anti–glomerular basement mem-
brane antibodies were negative. A kidney biopsy was
performed and showed glomerulonephritis with
vasculitis and crescents (Figure 1a and b) with negative
immunohistochemical stains conﬁrming the diagnosis
of perinuclear ANCA-associated pauci-immune vascu-
litis. Because of anorexia and fatigue, positron emission
tomography–computed tomography was performed
with high tracer uptake at the gastroesophageal junc-
tion and the right upper lobe of the lung. Thoracic
computed tomography showed ground glass opacities
suggestive of an inﬂammatory or infectious pulmonary
disease. Gastroscopy showed a polypoid lesion with a
maximal diameter of 2.5 cm at the gastroesophageal
junction (Figure 1c). Histopathological examination
revealed a moderately differentiated adenocarcinoma
with mucinous differentiation that was staged pT2N1M0.
The patient’s kidney function deteriorated progres-
sively, and she required intermittent hemodialysis
20 days after hospital admission. The patient subse-
quently underwent a curative partial esophagectomy.131
Table 1. Laboratory ﬁndings
Indicator At diagnosis 6 wk after esophagectomy 6 mo after esophagectomy 1 yr after esophagectomy Reference value
Creatinine level (mg/dl) 2.88 2.34 1.02 1.30 0.51–0.95
eGFR (ml/min per 1.73 m2) 17 22 59 43 (CKD-EPI)
u-RBC (per ml) Macroscopic hematuria 18 6 Negativea #25
Proteinuria (g/g creatinine) 1.76 0.90 0 .47 0.10 # 0.17
p-ANCAs (U/ml) 1 of 1280 1 of 320 1 of 80 Undetectable
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; mo, month(s); p-ANCAs, perinuclear antibodies against cytoplasmic antigens; wk, week(s); yr, year(s).
aNegative: <5 rbc/ml.
Figure 1. (a) Glomerulonephritis with crescents and vasculitis.
Recent segmental necrosis of the capillary loops, followed by
crescent formation. (b) Acute vasculitis: medium-sized artery
showing endothelial swelling, ﬁbrinoid necrosis, and a mixed in-
ﬂammatory cell inﬁltrate composed of neutrophils and lymphocytes.
(c) Polypoid lesion with a maximal diameter of 2.5 cm at the
gastroesophageal junction that is suggestive of an adenocarcinoma
at the gastroesophageal junction.
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following the operation: attenuation of paresthesia and
better gait, improvement of kidney function with no
further need for dialysis, and a decrease in ANCA titers
(1/320) after 6 weeks. Because of incomplete neuro-
logical and renal response, corticosteroids and ritux-
imab, 375 mg/m2, weekly were administered, starting 6
weeks postoperatively according to the Rituximab in
ANCA-Associated Vasculitis protocol. We opted for
this protocol because high-dose steroid monotherapy
was judged to not be appropriate as steroids are known
to impede wound healing after surgery (recent esoph-
agectomy) and because of the risk for development of
steroid myopathy (which would have further impeded
this patient’s ability to walk).
Treatment with rituximab led to further recovery of
kidney function 6 and 12 months after esophagectomy
and further diminishing of proteinuria and microscopic
hematuria 1 year after esophagectomy (Table 1). Also
clinically, the sensorimotor polyneuropathy recovered
markedly after the initiation of rituximab; there was a
progressive improvement in gait and a further increase
in muscle strength. Nevertheless, paresthesia persisted
in the lower limbs with a numb feeling in both legs. A
positron emission tomography–computed tomography
scan at 6 months’ follow-up showed an increased
metabolism at the neoesophagus that was suggestive of
inﬂammatory changes, which was conﬁrmed by
esophagogastroscopy. A follow-up positron emission
tomography–computed tomography scan after 1 year
showed no evidence of malignancy or vasculitis.
DISCUSSION
In general, AAV is idiopathic and appears to involve
genetically determined HLA speciﬁcities that allow the
autoimmune response to develop.7 The association of
AAV with solid tumors has been sporadically re-
ported.8–13 To the best of our knowledge, only 5 cases
of paraneoplastic ANCA vasculitis and gastrointestinal
cancers have been described before.11,13–16 Resolution
of vasculitis following effective treatment of the puta-
tively linked malignancy, and recurrence of vasculitis
heralding tumor recurrence or progression, would
provide strong evidence for vasculitis being a true132paraneoplastic syndrome.17 Of interest, only a few case
reports describe the response of paraneoplastic rapidly
progressive glomerulonephritis to treatment. Edgar
et al. reported a patient who experienced a remission of
renal disease after surgical resection in combination
with prednisone plus cyclophosphamide.10 In contrast,
Navarro et al. reported on a patient with AAV and a
concurrent undifferentiated adenocarcinoma in whom
treatment with prednisone and cyclophosphamide
resulted in remission of renal disease while there was
progression of the malignancy.18 Hosoya et al. reported
a case of ANCA-associated interstitial nephritis that
resolved after resection of a well-differentiated gastricKidney International Reports (2016) 1, 131–134
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74-year-old female patient with an myeloperoxidase-
ANCA pauci-immune glomerulonephritis with con-
current carcinomas of the stomach and duodenum.16
Resection of the tumors resulted in improvement of
renal function, disappearance of microscopic hematu-
ria, and a decrease in myeloperoxidase-ANCA levels.
However, proteinuria, elevated C-reactive protein
level, and cylindruria improved only following addi-
tional treatment with prednisolone.16 In our case the
patient had an esophageal cancer, for which she un-
derwent a curative partial esophagectomy, with partial
improvement of her condition afterward.
So our and other case reports suggest that AAV can
be paraneoplastic.19 The data linking cancer with the
occurrence of AAV are unequivocal. In a British study,
the frequency of preceding or concomitant cancer was
6-fold higher in the AAV group.9 In a German study,
no difference in prevalence of malignancy was found
between patients with granulomatosis with poly-
angiitis (GPA) and patients with rheumatoid arthritis,8
although the risk for a diagnosis of cancer 3 months
before or after diagnosis was substantially increased in
patients with GPA (odds ratio ¼ 18.00; 95% conﬁdence
interval: 2.30–140.67).8 In a Swedish study, bladder
carcinoma (preceding the diagnosis of GPA at a median
of 1.5 years) was twice as common in the cohort at the
time of diagnosis of vasculitis compared with in the
general population (relative risk ¼ 2.1; 95% conﬁdence
interval: 0.6–3.6).20 In contrast, in a Danish study the
prevalence of cancer at any site before the diagnosis of
vasculitis was not signiﬁcantly increased in the GPA
cohort (odds ratio ¼ 1.4, 95% conﬁdence interval:
0.9–2.2).21 Furthermore, the incidence of malignancies
in the ﬁrst years after a diagnosis of vasculitis was not
signiﬁcantly increased among patients with GPA.22
For idiopathic severe AAV, cyclophosphamide and
glucocorticoids or rituximab and glucocorticoids have
been the cornerstone of remission induction therapy.23
The Rituximab in ANCA-Associated Vasculitis trial
demonstrated that rituximab therapy was not inferior
to daily cyclophosphamide treatment for induction of
remission in severe AAV and may be superior in re-
lapsing disease.24 Because of the major surgery and
concurrent malignancy, we initially avoided the use of
steroids and cyclophosphamide in our patient. Because
of only partial resolution of vasculitis-associated signs
and symptoms after surgery, rituximab in combination
with corticosteroids were administered 6 weeks post-
operatively. This led to further clinical and biochemical
recovery and after more than 1 year of follow-up there
is no evidence of recurrence of her malignancy and
there are no signs of vasculitic disease activity. Our
report is the ﬁrst to demonstrate that rituximab can beKidney International Reports (2016) 1, 131–134safely administered to a patient with cancer-associated
AAV with only an incomplete response after treatment
of the underlying malignancy.
CONCLUSION
AAV could be paraneoplastic in nature, with remission
obtained after curative treatment of the underlying
malignancy. Here we have reported on a case of
myeloperoxidase-associated vasculitis in the context of
an esophageal cancer with substantial improvement
following resection of the malignancy. Rituximab was
administered because of incomplete response and
resulted in further renal and neurological improve-
ment. There was no recurrence of vasculitis or malig-
nancy after more than 1 year of follow-up.
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